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Abstract
Objective: Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular disease that causes skeletal muscle weakness,
including muscles involved with respiration. Death often results from respiratory failure within 3–5 years. Monitoring
respiratory status is therefore critical to ALS management, as respiratory/pulmonary function tests (PFTs) are used to
make decisions including when to initiate noninvasive ventilation. Understanding the different respiratory and PFTs as
they relate to disease progression and survival may help determine which tests are most suitable. Methods: This review
describes the tests used to assess respiratory muscle and pulmonary function in patients with ALS and the correlations
between different respiratory measures and clinical outcomes measures. Results: The most commonly used measurement,
forced vital capacity (VC), has been shown to correlate with clinical milestones including survival, but also requires good
motor coordination and facial strength to form a tight seal around a mouthpiece. Other tests such as slow VC, sniff
inspiratory pressure, or transdiaphragmatic pressure with magnetic stimulation are also associated with distinct advantages
and disadvantages. Conclusions: Therefore, how and when to use different tests remains unclear. Understanding how each
test relates to disease progression and survival may help determine which is best suited for specific clinical decisions.
Keywords: Non-invasive ventilation, amyotrophic lateral sclerosis, pulmonary function tests, slow vital capacity
Measuring respiratory function in
amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive
neuromuscular disease that causes skeletal muscle
weakness, including muscles that aid in respiration,
due to central and peripheral motor neuron degen-
eration. Respiratory failure associated with declining
muscle strength is the primary cause of death in
ALS patients and typically occurs within 3–5 years
(1). Moreover, approximately 3–5% of ALS patients
present with respiratory failure (2,3). As respiratory
function is directly related to skeletal muscle
function and patient survival, it is anticipated that
change in respiratory performance is reflective of
ALS progression.
However, measurement of respiratory function
in ALS patients is complicated by several factors.
For example, loss of facial muscle strength often
makes it difficult for patients to form a tight lip-seal
around a tube (4). Although a facemask or flanged
mouthpiece may be used in these patients (5,6),
there is still the potential for falsely low readings.
Additionally, marked spasticity associated with
concomitant upper motor neuron involvement,
cognitive impairment, and difficulties coordinating
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respiratory movements also have the potential to
confound respiratory measures (7). Bulbar muscle
dysfunction may result in nonvolitional glottic clos-
ure during forced expiratory maximal measures,
which can alter measurement accuracy (8,9).
Finally, the presence of concomitant diseases such
as obstructive lung disease can modify results of
pulmonary function tests (PFTs) (10), making it
difficult to estimate the contribution of respiratory
impairment for each illness.
Obstructive pulmonary disorders such as chronic
obstructive pulmonary disease (COPD) require
PFTs. However, because respiratory failure in ALS
is a result of neuromuscular weakness rather than
diseased airways, evaluation of respiratory function
in ALS requires different assessments than standard
PFTs. For example, obstructive pulmonary disease
is defined by a reduction in the rate of forced
expiration in 1 second (FEV1) as a function of
forced vital capacity (FVC) (FEV1/FVC) (11) and
as such this measurement is included in the
diagnostic criteria for COPD (12). However,
patients with restrictive lung diseases such as ALS
may have a normal FEV1 (13), making FEV1/FVC
ratio of limited value in these patients.
Clinical practice guidelines recommend routine
monitoring of respiratory symptoms in ALS patients
because symptoms of respiratory decline may be
masked by overall weakness. ALS patients frequently
have severe limb weakness before the onset of
respiratory involvement and therefore are unable to
exert themselves to the point of dyspnea, rendering
respiratory symptoms an insensitive marker for pul-
monary impairment (14). This is most evident in
patients with decreased mobility who may be unable
to walk (15).
According to American and European guidelines
(16,17), all ALS patients should have spirometry
measurements performed regularly after diagnosis.
Other recommendations include nocturnal pulse
oximetry, arterial blood gases (ABGs), polysomno-
graphy, maximal inspiratory pressure (MIP)/maximal
expiratory pressure (MEP), transdiaphragmatic pres-
sure (Pdi), or sniff nasal pressure (SNIP) if patients are
symptomatic and FVC is450% predicted (14). The
inclusion of these tests, in addition to FVC, may assist
with detecting changes in respiratory function early in
the disease course (18) and lead to institution of
supportive therapy with noninvasive ventilation
(NIV) (16,17).
Notwithstanding, respiratory muscle strength
tests and pulmonary function assessments are not
routinely used (19). In a 2009 survey of consultant
neurologists in the United Kingdom investigating
NIV use in patients with ALS, only 38% of
respondents reported assessing respiratory function
initially and only 20% routinely monitored it (20).
Therefore, it is clear that increased education about,
and standardization of the pulmonary measures that
are most useful in ALS, are needed.
Respiratory muscle and PFTs used in ALS
(Table 1)
Inspiratory measures
Inspiratory measures most commonly involve meas-
urements at the mouth (MIP) or nose (SNIP)
during a sudden rapid inhalation; to obtain the
maximum value, three trials are recommended for
MIP (21) and up to 10 trials for SNIP (21,22).
A normal value on either test requires both intact
central motor processing and a normally functioning
phrenic nerve. Both the diaphragm and sterno-
cleidomastoid muscles participate in inhalation;
sternocleidomastoid muscles contribute more
strongly to MIP, whereas the diaphragm generates
most of the force generated during SNIP (23). MIP
requires patients to inhale against an occluded
airway with maximum pressure generated measured
by a pressure transducer. This test is simple for
healthy subjects to perform, noninvasive, portable,
and inexpensive (24–26), and has well-established
reference values (24). However, it is effort-depend-
ent and difficult for some patients, especially for
those with facial weakness (25,26) and low values
can be difficult to interpret. Patients with significant
upper motor neuron burden may also find it difficult
to generate a rapid and coordinated forceful inhal-
ation. To perform a SNIP maneuver, patients inhale
through their noses (sniff) with one nostril occluded
with a probe connected to a pressure transducer
(26). There has been uncertainty about whether the
contralateral nostril should be occluded or not (27).
A recent study demonstrated that SNIP performed
with the contralateral nostril occluded yields higher
values and these correlate more closely with MIP,
demonstrating that the occluded technique is pref-
erable (27). This test is also simple, noninvasive,
portable, inexpensive (24,25), and easier for most
patients with facial weakness to perform (25);
however, it also requires effort (6), good central
motor control, and appears to be associated with a
learning effect in some patients over time (28).
Pdi, performed by inserting balloon catheters in
the stomach and mid-esophagus, and recording the
pressure difference across the diaphragm while
patients volitionally inspire, is the most accurate
and reproducible volitional inspiratory test, but is
also invasive and may not be well-tolerated (26).
However, Pdi with magnetic stimulation of the
phrenic nerve (29) is a passive test of the peripheral
nervous system, thus bypassing issues related to
central motor control. Although this test may
provide a more direct view of spinal motor neuron
integrity, it has the potential to under-represent
disease burden as central processes are not assessed.
In addition, although this measure is not effort- or
coordination-dependent, it does require equipment
that is not readily available and can be technically
challenging (24).
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Expiratory measures
Expiratory tests including MEP, cough peak flow
(CPF), peak expiratory flow (PEF), and cough
gastric pressure (cough Pga) require activation of
diaphragm and intercostal muscles and are affected
by impaired central motor control in the same
manner as volitional inspiratory tests. MEP requires
subjects to exhale maximally against an occluded
airway as the pressure is measured (14). Similar to
MIP, MEP is simple, noninvasive, and convenient
(30) with five trials recommended to obtain max-
imum value. However, it has the same limitations as
MIP (26). Thus, low MEP values may require
additional assessments such as CPF and cough Pga
(31). CPF uses a standard peak flow meter adapted
to an anesthesia face mask to measure a subject’s
ability to cough (26), whereas PEF is the maximum
flow rate generated during a forceful exhalation from
full inspiration (32,33). Cough Pga, measured by
passing a balloon catheter nasally to the stomach
and asking subjects to cough maximally until no
further increase of cough Pga is observed, is con-
sidered an excellent measure of expiratory muscle
strength; however, it is invasive and might not be
well-tolerated (31).
Vital capacity
Spirometry, which allows for the measurement of
vital capacity (VC), is the most frequently used
measure in ALS clinics (26). FVC is routine in the
clinical care of ALS patients (34) and is simple and
easy to perform (31,35). To perform a VC maneu-
ver, subjects must both inhale maximally and exhale
either rapidly (FVC) or slowly (SVC), recruiting
more muscle groups than either inspiratory or
expiratory tests. However, in addition to the need
for the facial muscle strength to form a tight seal
around the mouthpiece and good motor control
(4,6,36), VC is nonspecific in that it is reduced by
both obstructive and restrictive pulmonary disease
as well as by nonpulmonary factors such as obesity
(35). Clinicians should also be aware of the differ-
ences between supine versus upright readings and
how each reading can be helpful in monitoring ALS
(26). Specifically, supine FVC is typically lower than
upright FVC in both healthy subjects (up to 6.5%)
and in patients with restrictive lung diseases such as
ALS (up to 15%) (37–39); this suggests that supine
FVC may reveal abnormalities in diaphragm func-
tioning that upright FVC does not (40), thus
allowing clinicians to initiate NIV sooner. Finally,
a normal VC does not exclude the presence of
muscle weakness (14).
Recently, there has been a trend in ALS trials to
measure SVC rather than FVC (41). SVC has been
shown to provide interchangeable information with
FVC regarding respiratory function in ALS patients
(42), but is easier to perform, especially in patients
with significant upper motor neuron burden or withT
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severe respiratory dysfunction. Patients with severe
bulbar disease have difficulties with FVC because
the upper airway collapses when maximal effort is
exerted (43), and patients in general have a ten-
dency to cough during forced exhalation (44). In
addition, FVC but not SVC, has been shown to
underestimate true VC in the presence of concomi-
tant obstructive lung disease (45).
Maximum voluntary ventilation
Maximum voluntary ventilation (MVV), a measure
of respiratory muscle endurance, requires patients to
breathe as deeply and quickly as possible for
12 seconds (10) for at least two trials. Although it
has been shown to be a sensitive measure of ALS
disease progression overall (46), it is not sensitive to
small changes in muscle strength early in the disease
(18) and is difficult to follow over time because
some patients have difficulty performing the man-
euvers (14). In addition, it may also be reduced in
patients with coexisting obstructive lung disease and
interstitial lung diseases (10), complicating the
interpretation of the results. MVV generally does
not provide information not found with standard
spirometry. Given the challenges of performing this
test, it is not frequently used.
Other measures of pulmonary function
Measurements of gas exchange (e.g. pulse oximetry,
ABGs, transcutaneous/end tidal carbon dioxide
[CO2]) are also used to monitor respiratory function
in ALS patients and are recommended for patients
with severe bulbar impairment (47,48). Nocturnal
pulse oximetry, which involves measuring oxygen
saturation throughout the night via transcutaneous
finger probes (49), and ABGs, assessed from blood
samples drawn from the radial artery while patients
breathe room air, are used to evaluate nocturnal
hypoventilation, which is an indicator for urgent
evaluation for NIV or palliative care (48). Nocturnal
pulse oximetry values are a prognostic indicator of
survival (50); however, arterial hypoxemia occurs
relatively late in hypoventilation (51). ABGs also
have limited value in early disease (14) as CO2 levels
generally rise late in ALS disease course (1).
Phrenic nerve motor response assessed by percu-
taneous electrical stimulation at the neck is a simple,
nonvolitional test that provides information about
the functional preservation of the diaphragm. Motor
amplitude is an independent predictor of hypoven-
tilation (52) and survival (53), and the size of the
motor response is related to respiratory symptoms in
ALS (54). Non-invasive transabdominal ultrasonog-
raphy allows for direct, dynamic assessment of
diaphragm motion (55), and diaphragm thickness
has been correlated with FVC (56).
The evaluation of respiratory muscle function in
ALS is critical for the timing of respiratory
interventions and for overall prognosis. However,
routinely performed tests, for example, FVC, need
to be specifically correlated with clinical outcomes
and may be poorly informative particularly in
patients with severe bulbar dysfunction or fronto-
temporal dementia, limiting their usefulness.
Correlations between different respiratory
measures and between the measures and
clinical outcomes
Overview
Given the wide range of tests available determining
which respiratory function test(s) to use and when is
critical, especially when making decisions regarding
initiating NIV, which can increase survival (57–61)
and improve quality of life (58,61,62). Optimal
timing of NIV initiation remains controversial (16).
Additional research may provide a more complete
understanding of the relationships among the dif-
ferent tests as they relate to disease progression and
ultimately survival and may help determine which
test is best suited.
Respiratory measures and survival
Some respiratory tests have been shown to predict
survival in ALS (1,60,63–70). For example, a single
FVC value obtained at an initial visit was shown to
serve as a clinically meaningful predictor of survival
(1,65), and a retrospective analysis of placebo-
treated ALS patients from two large clinical trials
(EMPOWER and BENEFIT-ALS) and an ALS trial
database (PRO-ACT) found that rate of decline in
SVC strongly predicts the likelihood of death (63).
Another study found that the decrease in the
percentage of predicted values of both FVC and
SVC are strong predictors of survival in patients
with ALS (67). A review of results from numerous
PFTs from ALS patients over 8 years found that
the risk of death was significantly associated with the
decline in pulmonary function, regardless of the
PFT parameter (e.g. SVC, MIP, SNIP, MEP, PFC),
although compared with SVC, the MIP, SNIP, and
MEP values were decreased earlier in disease
course, decreased more rapidly within months
before death, and were affected by learning effect
(66). Maximal esophageal pressure (Ppl, max),
which is used to assess respiratory mechanism, has
also been shown to be predictive of survival, with a
Ppl, max530 cmH2O associated with significantly
greater mortality (70). Finally, a cohort study of
ALS patients at a single, tertiary care academic
medical center from 1997 to 2002 found that supine
FVC, and upright FVC, MIP, MEP, and Pdi-sniff
values to be significantly associated with tracheos-
tomy-free survival, and that normal supine FVC,
MIP, or MEP values were highly predictive for
1-year survival (68).
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However, not all test results appear to be equally
predictive of survival. Schmidt et al. (68), for
instance, found no significant association between
partial pressure of CO2 and survival. This finding is
supported by a retrospective study that found that
although abnormal daytime partial pressure of
oxygen, partial pressure of CO2, and oxygen satur-
ation from daytime arterial gas analyses appeared to
be associated with shorter survival, this association
was not statistically significant (60). In addition, two
studies from Europe found that SNIP value was a
good predictor of tracheostomy or death compared
with FVC (71,72).
Respiratory measures and clinical outcomes/
milestones
The use of respiratory measures to predict the time
to ventilation and/or death has also been studied
(63,69,71,73). For example, the recent retrospective
analysis of placebo-treated patients from
EMPOWER, BENEFIT-ALS, and PRO-ACT also
found that a decline in SVC strongly predicted
respiratory failure and tracheostomy (63).
Additionally, a retrospective analysis of serial data
of five respiratory function tests (FVC, PCF, MIP,
MEP, and SNIP) in ALS patients found that
although all five tests showed a descending trend
during disease progression, SNIP showed the great-
est decline within the latest 3 months before NIV
was indicated and that PCF at referral to the first
home ventilation service visit was significantly
associated with NIV indication (73). A study of
ALS patients enrolled at a multidisciplinary tertiary
care center for motor neuron disease found that
those who underwent tracheostomy or who had died
presented with significant differences in SNIP
(p50.001) and FVC values at baseline (p¼ 0.023)
compared with patients who did not reach these
outcomes (71). These results suggest the possibility
that certain respiratory function tests might better
predict survival or time to certain disability mile-
stones in ALS patients than others. However, as
analyses comparing all available tests and in all ALS
stages have not been performed, one specific
respiratory test with the greatest predictive value
for respiratory decline and patient survival cannot
be identified at this moment, indicating that add-
itional research is warranted.
Studies examining the use of respiratory meas-
ures to predict clinical outcomes and measurements,
including strength, respiratory failure, and/or the
revised ALS Functional Rating Scale scores have
generally focused on VC (38,42,69,74). For
instance, Shefner et al. found that changes in
hand-held dynamometry megascores, as measured
in two double-blind, randomized, placebo-
controlled phase 3 studies of ceftriaxone (75) and
dexpramipexole (76), were well-correlated with
SVC (74), and Pinto and de Carvalho found a
weak yet significant correlation between the revised
ALS Functional Rating Scale and FVC/SVC
(p50.001) (42).
Cross correlations of respiratory measures
Due to its extensive use in clinical trials, FVC has
historically been the most commonly used com-
parative measure (Table 2). However, studies
examining the relationships between VC and other
respiratory measures have yielded variable results
likely related to different methodologies used in the
different studies. For example, when pulmonary
function (FVC) and respiratory muscle strength
(MIP, MEP, and SNIP) were assessed in ALS
patients and matched healthy subjects, a positive
correlation was recorded between FVC/SNIP,
FVC/MIP, and FVC/MEP in ALS patients (19).
However, a prospective, randomized study of 20
ALS patients found no correlation between FVC
and MIP, MEP, or peak cough expiratory flows
(38). A recent study of ALS patients found a strong
correlation between FVC and SVC; both were also
correlated with MIP and MEP (42).
Conclusions
Measuring respiratory function is clearly critical for
monitoring ALS progression. Although multiple
tests have been shown to predict survival, they
measure different aspects of pulmonary function. In
addition, although some studies have shown correl-
ation between different measures and with clinical
outcomes these conclusions are generally derived
from data collected in clinical trials and, as such,
from a specific population of ALS patients who are
typically younger, more motivated, and without
cognitive involvement.
Additional research, especially population-based
respiratory studies, is needed to provide information
to support decisions regarding which respiratory
tests are most useful and at which stage of disease.
In addition, it would be helpful to establish the
relative sensitivity of each test to specific aspects of
respiratory function to know if some tests are more
sensitive to early changes in respiratory muscle
function and whether others are more useful as
disease progresses.
It is the opinion of the authors that FVC or SVC
should be measured at ALS diagnosis and every 3
months thereafter. As noted, although FVC and
SVC are highly correlated, there is some evidence
that some patients perform one more reliably than
the other. It is reasonable to measure both tests and
use the one yielding a higher result with lower
variability between efforts. Furthermore, it is
important that whoever is administering the tests is
trained and familiar with guidelines for acceptable
test quality and should work to ensure high-quality
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test results. Unreliable results can be misleading and
may result in unnecessary interventions.
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